NEWS: Today we announced the publication in?Nature Communications?of results from Replicate’s FIH Phase I clinical study of our srRNA rabies vaccine, RBI-4000. ? Very exciting validation for the demonstration of this technology with the potential to usher in a new era for RNA medicines. The data suggest RBI-4000 could offer a meaningful improvement over currently available options for rabies. Rabies is a vaccine-preventable, neglected tropical disease that is responsible for claiming over 60 lives per year. ? Congratulations to Christian Maine, Ph.D., Shigeki Miyake-Stoner, Darina Spasova, Ga?lle Picarda, Annie Chou, Emily Brand, Melanie Olesiuk, Christine Domingo, Hunter Little, Thomas (Ty) Goodman, Jacqueline Posy, Jasmin Gonzalez, Terrina Bayone, Jessica Sparks, Ebony Gary, Zhi Xiang, Nicholas Tursi, Casey Hojecki, Hildegund C. J. Ertl, David B. Weiner, Irafasha C. Camil, Anna Blakney, Brandon Essink, Guillermo Somodevilla, Nathaniel Wang, Andy Geall, Zelanna Goldberg, M.D., M.A.S., and Parinaz (Paris) Aliahmad! Learn more: https://lnkd.in/ec_yv5-P #RNA #mRNA #srRNA #saRNA #Vaccines #Publication #Biotech?Nature Nature Magazine
关于我们
Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and the RNA encoding therapeutic proteins. Our library of viral vectors, selected for driving robust and sustained protein expression and orders-of-magnitude improved performance over linear mRNA, allow for the development of treatments in applications including oncology, infectious disease, and autoimmunity. Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more.
- 网站
-
https://www.replicatebioscience.com
Replicate Bioscience, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
10210 Campus Point Dr
#150
US，California，San Diego，92121
Replicate Bioscience, Inc.员工
动态
-
The Replicate team will be kicking off the New Year at the J.P. Morgan 43rd?Annual Healthcare Conference taking place January 13-16 in San Francisco. Contact us to schedule meetings with CEO Nathaniel Wang and CBO Rachael Lester at the event. #biotech #srRNA #mRNA #RNA?
-
-
Replicate CEO Nathaniel Wang and CBO Rachael Lester will be at the Piper Sandler 36th?Annual Healthcare Conference held December 3-5 in NYC.?Reach out to schedule 1:1s and hear more about our latest company updates - we hope to see you there! #srRNA #biotech #mRNA #RNA #vaccine
-
-
Don’t miss our presentation today at the 12th?International mRNA Health Conference! Replicate’s Head of Research and Development, Parinaz (Paris) Aliahmad, will share data from our rabies clinical trial showing the expanded therapeutic index of a novel, optimized srRNA vaccine. #RNA #mRNA #srRNA #Vaccines #Biotech #mRNAHealthConference
-
-
Catch Replicate CDO, Andy Geall, at AMM ASCENT—the first annual meeting of the Alliance for mRNA Medicines—this week in Boston! Learn more about the event and register:?https://lnkd.in/e4JzQMf4 #RNA #mRNA #srRNA #vaccines #RNAtherapeutics
I'm attending the 1st Annual meeting AMM ASCENT. AMM was launched a year ago in November at the mRNA Health 2023 conference in Berlin and I was pleased to accept the role a Chair of the Board. It’s hard to believe 12 months have passed and we are now having our 1st annual meeting, which starts at the end of the mRNA Health 2024 conference in Boston and in the same location.
-
-
On November 14th, our CBO Rachael Lester will participate in a roundtable hosted by Financial Times focused on funding biopharma innovation to discuss asset development, corporate growth, and stakeholder communication in a complex and evolving macroeconomic environment. #Biotech #BusinessDevelopment #Industry?
-
-
Mark your calendar: Next week, our Head of Research & Development, Parinaz (Paris) Aliahmad, will present clinical data demonstrating the expanded therapeutic index of a novel srRNA vaccine at the 12th?International mRNA Health Conference in Boston. We hope to see you there! #mRNA #RNA #srRNA #vaccines #mRNAHealthConference #Biotech
-
-
Next week, our CDO Andy Geall and CBO Rachael Lester will visit Sao Paulo to attend the Developing Countries Vaccine Manufacturers Network (DCVMN International) 25th Annual General Meeting. We look forward to insightful discussions on prioritizing accessibility in vaccine development, manufacturing, and roll out to ensure that scientific advancements benefit all populations. Learn more about DCVM International here:?https://lnkd.in/ec8up_X2 #vaccines #manufacturing #srRNA #mRNA #RNAresearch
-
-
Replicate CBO Rachael Lester is heading to NYC next week to present at the Oppenheimer & Co. Inc. Private Healthcare Company Showcase. Reach out to schedule meetings and learn more about how we’re expanding the therapeutic utility of #RNA with our next gen #srRNA vectors. #biotech #mRNA #RNAtherapeutics #vaccine
-
-
San Diego has a lot to be proud of as a true hub of scientific innovation, including being a premier location for #RNATherapeutics research and development! At Connect’s 3rd Annual Innovation Day, Replicate CDO and Co-founder Andy Geall will showcase the positive impact of RNA medicines on public health. See you in Petco Park! #SanDiego #IDSD24 #RNA #mRNA #srRNA #Vaccine #Biotech
I’m thrilled to announce that I’ll be speaking at Innovation Day, hosted by @Connect, on September 24th at Petco Park! This event is a convergence of technology, life sciences, and innovation—a step into the future right here in San Diego. It’s an incredible opportunity to connect with industry leaders and visionaries, and explore what’s driving innovation in our region. Join me at #IDSD24: sandiegoisbetter.com
-